Intellia Pauses Nex-Z Phase 3 Trials After Grade 4 Liver Event

Intellia places its CRISPR gene editing therapy nex-z on partial clinical hold following a serious liver adverse event, raising questions about in vivo LNP-delivered editing safety at scale. Over 450 patients had been dosed across MAGNITUDE trials.